查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1715627

甲狀腺眼疾藥物市場依治療類型、給藥途徑、類型、診斷、最終使用者和分佈分類－2025-2030 年全球預測

Thyroid Eye Disease Treatments Market by Treatment Type, Route of Administration, Type, Diagnosis, End-User, Distribution - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

甲狀腺眼疾治療市場規模預計在 2024 年為 26.7 億美元，預計在 2025 年成長至 28.3 億美元，複合年成長率為 5.94%，預計在 2030 年達到 37.8 億美元。

主要市場統計數據
基準年2024年 26.7億美元
預計2025年 28.3億美元
預測年份 2030 37.8億美元
複合年成長率（%） 5.94%

甲狀腺眼疾 (TED) 既具有臨床複雜性，又具有不斷發展的治療機會，這些機會正在重塑醫療保健提供者管理這種具有挑戰性的疾病的方式。近年來，在理解​​潛在病理和實施多種治療策略（從保守的醫療干預到手術治療）方面取得了顯著進展。本執行摘要深入探討了 TED 治療的多方面前景，詳細介紹了重新定義患者照護的科學進步和策略見解。本介紹將重點放在當前護理環境的關鍵方面，強調治療和診斷方法的創新如何影響臨床決策和改善患者的治療效果。隨著研究的深入和新治療方法的出現，相關人員正在見證臨床實踐的轉變，這需要可靠的分析和策略遠見。不斷發展的治療方法凸顯了需要一種綜合的觀點，不僅要考慮生物和臨床因素，還要考慮塑造治療模式的市場動態和監管促進因素。這項詳細的審查為決策者提供了開創性的概述，並為後續章節的更深入理解和策略討論鋪平了道路。

重新定義甲狀腺眼疾治療前景的轉捩點

近年來，在科學創新和市場動態的推動下，甲狀腺眼疾治療模式發生了重大變革時期。先進的影像技術和增強的診斷通訊協定改變了臨床醫生診斷和分類 TED 的方式，從而可以更早進行干預並製定更有針對性的治療策略。標靶治療的出現，特別是在免疫調節和生物製藥領域，反映了向個人化醫療的更廣泛轉變。這些進步與對微創手術的日益重視相結合，以補充傳統的醫療方法。隨著臨床實踐的發展，經濟考量和醫療保健政策將進一步影響治療選擇和研發投資。這種轉變不僅改變了治療方法組合，也拓寬了病患管理的範圍，並整合了內分泌科醫生、眼科醫師和外科專家之間的多學科合作。生態系統的全面轉變凸顯了技術整合、策略夥伴關係和監管適應的關鍵作用。這種情況要求該領域的領導者將策略願景與創新相結合，以解決未滿足的需求並提高護理的有效性和品質。這種動態環境需要採取積極主動的方法來適應快速變化並利用新的研究和臨床機會。

關鍵細分洞察助力目標定位策略

仔細分析市場區隔可以揭示對於制定有針對性且有效的 TED 治療策略至關重要的詳細結構。在考慮治療類型時，市場明確區分醫療介入和外科手術介入。在醫療領域，已經詳細分析了各種治療方法，包括皮質類固醇、免疫抑制劑、單株抗體、甲狀腺激素調節劑和蛋白酪氨酸激酶抑制劑。相反，手術治療策略包括眼瞼手術、眼眶減壓術和斜視手術。除了治療方式外，給藥途徑（靜脈注射、口服或局部）也被視為決定療效和病人依從性的關鍵因素。此外，根據疾病類型（I 型 TED 和 II 型 TED）對市場進行細分，可以更清楚地制定干涉措施。診斷技術形成另一個關鍵的細分層，透過血液檢查、影像檢查、眼眶超音波、放射性碘攝取測試等各種測試來追蹤市場。分析涵蓋最終用戶，從醫院和門診中心到專科診所，每個用戶都帶來了獨特的機會和挑戰。最後，分銷通路發揮關鍵作用，醫院藥局網路、網路藥局、傳統零售藥局等監督市場。細分的每個方面都有助於描述化合物，不僅闡明了當前的趨勢，而且還指導了未來的研究、投資決策和臨床策略。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 全球甲狀腺疾病的發生率和盛行率不斷上升，迫切需要有效的治療方法。
      • 提高醫療保健專業人員對甲狀腺眼疾症狀和治療方法的認知
    • 限制因素
      • 甲狀腺眼疾治療產品頻繁召回引發擔憂
    • 機會
      • 製藥公司與研究機構持續合作，強化甲狀腺眼疾治療
      • 甲狀腺眼疾治療的創新帶來新的和更好的治療方法
    • 任務
      • 目前治療甲狀腺眼疾的藥物的潛在副作用和不良反應
  • 市場區隔分析
    • 治療類型：患者越來越需要透過手術治療來恢復視覺功能和美觀。
    • 給藥途徑：靜脈注射因其有效性和作用速度而更受青睞。
    • 類型：甲狀腺眼疾藥物在治療 I 型 TED 中抑制發炎和防止進展的重要性
    • 診斷：眼眶超音波由於其非侵入性和成本效益而變得越來越重要。
    • 最終用戶：隨著對便利、經濟有效的治療方案的需求不斷成長，門診中心擴大採用甲狀腺眼疾藥物
    • 配送：無縫取得專科護理使得醫院藥局變得越來越重要
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

6. 甲狀腺眼疾治療市場（依治療類型）

  • 治療
    • 皮質類固醇
    • 免疫抑制劑
    • 單株抗體
    • 甲狀腺激素控制
    • 蛋白酪氨酸激酶抑制劑
  • 手術治療
    • 眼瞼手術
    • 眼眶減壓手術
    • 斜視手術

7. 甲狀腺眼疾治療市場（依給藥途徑）

  • 靜脈
  • 口服
  • 話題

8. 甲狀腺眼疾治療市場（依類型）

  • I型TED
  • II型TED

9. 甲狀腺眼疾治療市場（依診斷）

  • 血液檢查
  • 影像檢查
  • 眼眶超音波
  • 放射性碘攝取量測試

第 10 章 甲狀腺眼疾治療市場（依最終使用者）

  • 醫院
  • 門診中心
  • 專科診所

第11章 甲狀腺眼疾治療市場（依分佈）

  • 醫院藥房
  • 網路藥局
  • 零售藥局

12.美洲甲狀腺眼疾治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

13.亞太甲狀腺眼疾藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

14.歐洲、中東和非洲甲狀腺眼疾藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第15章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Abbott Laboratories
  • AbbVie Inc.
  • ACELYRIN, INC.
  • Amgen Inc.
  • argenx SE
  • Bausch & Lomb Incorporated
  • Biocon Limited
  • BioXpress Therapeutics SA
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Genmab A/S
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Hetero Drugs Limited
  • Immunovant, Inc.
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson Services Inc.
  • Lupin Limited
  • Merck KGaA
  • Novartis AG
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sling Therapeutics, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viridian Therapeutics, Inc.
Product Code: MRR-033332D2AF77

The Thyroid Eye Disease Treatments Market was valued at USD 2.67 billion in 2024 and is projected to grow to USD 2.83 billion in 2025, with a CAGR of 5.94%, reaching USD 3.78 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 2.67 billion
Estimated Year [2025] USD 2.83 billion
Forecast Year [2030] USD 3.78 billion
CAGR (%) 5.94%

Thyroid eye disease (TED) presents both clinical complexities and evolving therapeutic opportunities that are reshaping the manner in which healthcare providers manage this challenging condition. Over recent years, remarkable progress has been made in understanding the underlying pathology and implementing diverse treatment strategies, from conservative medical interventions to surgical remedies. This executive summary delves into the multifaceted landscape of TED treatments, detailing the scientific advances and strategic insights that have redefined patient care. In this introductory section, the focus is on framing the critical aspects of the current treatment environment, highlighting how innovations in therapy and diagnostic methodologies are influencing clinical decisions and improving patient outcomes. As research deepens and new treatment modalities emerge, stakeholders are witnessing a transformation in clinical practice that demands robust analysis and strategic foresight. The evolution in therapeutic approaches underscores the necessity of an integrative perspective-one that not only considers the biological and clinical factors but also the market dynamics and regulatory drivers that shape treatment paradigms. This detailed exploration serves as a ground-breaking overview for decision-makers, paving the way for a deeper understanding and strategic discussion throughout the subsequent sections.

Transformative Shifts Redefining the Thyroid Eye Disease Treatment Landscape

In recent years, the landscape of thyroid eye disease treatment has undergone significant transformative shifts, driven by both scientific innovations and changing market dynamics. Advanced imaging technologies and enhanced diagnostic protocols have reshaped how clinicians diagnose and classify TED, enabling earlier intervention and more tailored treatment strategies. The emergence of targeted therapies, particularly in the realm of immunomodulatory and biologic treatments, reflects a broader shift toward personalized medicine. These advances are coupled with a growing emphasis on minimally invasive surgical procedures that complement traditional medical treatments. As clinical practices evolve, economic considerations and healthcare policies further influence treatment selections and investment in research and development. This transformation is not only altering the therapeutic mix but also broadening the scope of patient management, integrating multi-disciplinary collaborations between endocrinologists, ophthalmologists, and surgical experts. The comprehensive changes within this ecosystem highlight the critical role of technological integration, strategic partnerships, and regulatory adaptations. In this context, leaders in the field are urged to align their strategic vision with innovations that address unmet needs and improve both the efficacy and quality of care. This dynamic environment demands a proactive approach to adapt to rapid changes and to harness emerging opportunities in research and clinical practice.

Key Segmentation Insights Informing Targeted Strategies

A careful dissection of market segmentation reveals a detailed structure that is crucial for crafting targeted and effective strategies for TED treatments. When considering treatment types, the market distinctly differentiates between medical and surgical interventions. The medical treatment arm is meticulously analyzed through a spectrum of therapies that include corticosteroids, immunosuppressants, monoclonal antibodies, agents for thyroid hormone control, and tyrosine kinase inhibitors. Conversely, surgical treatment strategies are further explored through procedures such as eyelid surgery, orbital decompression surgery, and strabismus surgery. In tandem with treatment modality, the route of administration-a key determinant of both efficacy and patient compliance-has been scrutinized in terms of intravenous, oral, and topical applications. Additionally, segmenting the market by disease type, namely between Type I TED and Type II TED, offers further clarity in tailoring interventions. Diagnostic methodologies form another important segmentation layer that tracks the market through various tests including blood tests, imaging tests, orbital ultrasound, and radioactive iodine uptake tests. Analysis extends to the end-user dimension, where care settings span from hospitals and outpatient centers to specialty clinics, each presenting unique opportunities and challenges. Finally, distribution channels play a critical role, with market oversight including hospital pharmacy networks, online pharmacies, and traditional retail pharmacies. Each segmentation facet contributes to a compounding narrative that not only illuminates current trends but also directs future research, investment decisions, and clinical strategies.

Based on Treatment Type, market is studied across Medical Treatment and Surgical Treatment. The Medical Treatment is further studied across Corticosteroids, Immunosuppressants, Monoclonal Antibodies, Thyroid Hormone Control, and Tyrosine Kinase Inhibitors. The Surgical Treatment is further studied across Eyelid Surgery, Orbital Decompression Surgery, and Strabismus Surgery.

Based on Route of Administration, market is studied across Intravenous, Oral, and Topical.

Based on Type, market is studied across Type I TED and Type II TED.

Based on Diagnosis, market is studied across Blood Test, Imaging Test, Orbital Ultrasound, and Radioactive Iodine Uptake Test.

Based on End-User, market is studied across Hospitals, Outpatient Centers, and Specialty Clinics.

Based on Distribution, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.

Key Regional Insights Shaping Global Market Dynamics

The TED treatment market is characterized by distinct regional variations, reflecting both local healthcare infrastructure and regional economic dynamics. In the Americas, robust healthcare spending, coupled with strong research and development initiatives, creates a fertile ground for innovation and rapid adoption of advanced therapeutic modalities. Meanwhile, Europe, Middle East & Africa experience a blend of mature healthcare markets and emerging opportunities, driven by a careful balance between tradition and innovation. European nations, in particular, continually enhance diagnostic technologies and treatment protocols, while markets in the Middle East and Africa adapt rapidly to dynamic demand patterns through strategic partnerships and policy reforms. The Asia-Pacific region stands out with its fast-growing healthcare infrastructure and increasing investment in research, making it a pivotal arena for both new market entrants and established players. These regional insights underscore the critical need for tailored strategies that address local demands while leveraging global best practices. Interregional differences in regulatory frameworks, reimbursement policies, and patient preferences remain at the core of strategic decision-making processes that drive market growth and innovation.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, New Jersey, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights Highlighting Competitive Landscape and Innovation

The competitive arena of thyroid eye disease treatment is populated by a diverse group of key companies that drive innovation, invest in advanced research, and expand their market presence. Market leaders including Abbott Laboratories, AbbVie Inc., ACELYRIN, INC., Amgen Inc., argenx SE, and Bausch & Lomb Incorporated are at the forefront of developing novel therapeutic interventions and enhancing patient care. In addition, companies such as Biocon Limited, BioXpress Therapeutics SA, Cipla Limited, and Dr. Reddy's Laboratories Ltd. continue to push the boundaries of both medical and surgical treatment options. Prominent names such as Eli Lilly and Company, F. Hoffmann-La Roche AG, Genmab A/S, GlaxoSmithKline PLC, and H. Lundbeck A/S reaffirm the commitment to robust innovation pipelines and targeted clinical solutions. Hetero Drugs Limited, Immunovant, Inc., Intas Pharmaceuticals Ltd., and Johnson & Johnson Services Inc. bring to the table significant advancements and an acute understanding of market needs. The competitive landscape is further enriched by Lupin Limited, Merck KGaA, Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sling Therapeutics, Inc., Teva Pharmaceutical Industries Ltd., and Viridian Therapeutics, Inc., each contributing distinct approaches that range from breakthrough therapies to enhanced surgical techniques. This confluence of expertise reinforces the industry's multifaceted approach in addressing the clinical complexities of thyroid eye disease and sets the stage for future growth and competitive differentiation.

The report delves into recent significant developments in the Thyroid Eye Disease Treatments Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., ACELYRIN, INC., Amgen Inc., argenx SE, Bausch & Lomb Incorporated, Biocon Limited, BioXpress Therapeutics SA, Cipla Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, Genmab A/S, GlaxoSmithKline PLC, H. Lundbeck A/S, Hetero Drugs Limited, Immunovant, Inc., Intas Pharmaceuticals Ltd., Johnson & Johnson Services Inc., Lupin Limited, Merck KGaA, Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sling Therapeutics, Inc., Teva Pharmaceutical Industries Ltd., and Viridian Therapeutics, Inc.. Actionable Recommendations for Navigating the Transformative Market

Industry leaders are encouraged to adopt a proactive and strategic approach in order to capitalize on the rapidly transforming landscape of thyroid eye disease treatments. Stakeholders should prioritize investment in innovative therapeutic research, particularly in the sphere of targeted biologics and minimally invasive surgical techniques. Given the nuanced segmentation across treatment types, routes of administration, disease types, and diagnostic protocols, it is essential to develop tailored strategies that address individual patient profiles and local market dynamics. Emphasis should be placed on integrating advanced diagnostic tools and data analytics into routine clinical practice, which not only improves precision but also facilitates early intervention. Furthermore, forging robust strategic alliances, both on a regional and cross-regional level, can help in pooling expertise and expediting the adoption of best practices. There is a clear imperative for optimizing distribution networks to ensure timely accessibility of therapies, alongside streamlining processes within hospital and online pharmacy channels. Overall, a deepened focus on understanding market segmentation, regional disparities, and the competitive landscape will provide industry leaders with the insights needed to mitigate risk and harness the substantial opportunities inherent in this evolving therapeutic domain.

Conclusion: Embracing a Future of Innovation and Personalized Care

In conclusion, the landscape of thyroid eye disease treatments is characterized by a dynamic interplay between innovation, strategic market segmentation, and evolving regional dynamics. As stakeholders navigate the complex therapeutic ecosystem, it is imperative to consider the diversity of treatment modalities, ranging from cutting-edge medical interventions to refined surgical techniques. The in-depth segmentation analysis - encompassing treatment type, route of administration, disease classification, diagnostic methodology, end-user setting, and distribution channels - has revealed not only the intricacies of current practices but also the directions for future innovation and strategic planning. Moreover, regional insights indicate that while the Americas and Europe, Middle East & Africa provide robust infrastructure and progressive policy environments, the Asia-Pacific market offers immense potential with its rapid expansion and increasing research investments. Coupled with the competitive drive of leading companies, the market is poised for transformative growth that prioritizes personalized care and data-driven decision making. This comprehensive review underscores the necessity for adaptability and strategic foresight among clinicians, manufacturers, and policy makers, all of whom play pivotal roles in shaping the future of TED treatment paradigms.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising global incidence and prevalence of thyroid disorders necessitates effective treatment options
      • 5.1.1.2. Increasing awareness about symptoms and treatments for thyroid eye disease among healthcare providers
    • 5.1.2. Restraints
      • 5.1.2.1. Concern associated with frequent product recalls of thyroid eye disease treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing collaborations between pharmaceutical companies and research institutions enhancing thyroid eye disease treatment product
      • 5.1.3.2. Rising advancements in innovation of thyroid eye disease treatment to enhance novel therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Potential side effects and adverse reactions associated with current thyroid eye disease treatments
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Type: Increasing need for surgical treatments to restore visual function and cosmetic appearance among patients
    • 5.2.2. Route of Administration: Rising preference for intravenous administration owing to efficacy and immediate relief
    • 5.2.3. Type: Significant importance of thyroid eye disease treatments for treating type I TED for controlling inflammation and preventing progression
    • 5.2.4. Diagnosis: Increasing significance for orbital ultrasound owing to its non-invasive appeal and cost-effectiveness
    • 5.2.5. End-User: Expanding adoption of thyroid eye disease treatments across outpatient centers with rising need for convenient and cost-effective treatment solutions
    • 5.2.6. Distribution: Growing importance of hospital pharmacies owing to seamless access to specialized treatments
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Thyroid Eye Disease Treatments Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Medical Treatment
    • 6.2.1. Corticosteroids
    • 6.2.2. Immunosuppressants
    • 6.2.3. Monoclonal Antibodies
    • 6.2.4. Thyroid Hormone Control
    • 6.2.5. Tyrosine Kinase Inhibitors
  • 6.3. Surgical Treatment
    • 6.3.1. Eyelid Surgery
    • 6.3.2. Orbital Decompression Surgery
    • 6.3.3. Strabismus Surgery

7. Thyroid Eye Disease Treatments Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Intravenous
  • 7.3. Oral
  • 7.4. Topical

8. Thyroid Eye Disease Treatments Market, by Type

  • 8.1. Introduction
  • 8.2. Type I TED
  • 8.3. Type II TED

9. Thyroid Eye Disease Treatments Market, by Diagnosis

  • 9.1. Introduction
  • 9.2. Blood Test
  • 9.3. Imaging Test
  • 9.4. Orbital Ultrasound
  • 9.5. Radioactive Iodine Uptake Test

10. Thyroid Eye Disease Treatments Market, by End-User

  • 10.1. Introduction
  • 10.2. Hospitals
  • 10.3. Outpatient Centers
  • 10.4. Specialty Clinics

11. Thyroid Eye Disease Treatments Market, by Distribution

  • 11.1. Introduction
  • 11.2. Hospital Pharmacy
  • 11.3. Online Pharmacy
  • 11.4. Retail Pharmacy

12. Americas Thyroid Eye Disease Treatments Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Thyroid Eye Disease Treatments Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Thyroid Eye Disease Treatments Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Sling Therapeutics reveals advance phase 2b/3 trial results for linsitinib in thyroid eye disease management
    • 15.3.2. Acelyrin, Inc. announces new Phase 2 data and Phase 3 plans for lonigutamab in treating thyroid eye disease
    • 15.3.3. Lundbeck launches advance clinical trial of CD40L blocker Lu AG22515 targeting thyroid eye disease
    • 15.3.4. Amgen announced TEPEZZA approval in Japan marks a significant advancement in thyroid eye disease treatment
    • 15.3.5. Viridian Therapeutics enhances with Phase III trials of VRDN-003 for treating thyroid eye disease
    • 15.3.6. Verana Health announces launch of Qdata thyroid eye disease
    • 15.3.7. Xeris Biopharma finalizes worldwide licensing agreement for Xeriject teprotumumab in thyroid eye disease treatment
    • 15.3.8. Viridian Therapeutics partners with Ypsomed AG to enhance subcutaneous thyroid eye disease treatment
    • 15.3.9. Amgen completes acquisition of Horizon Therapeutics to expand rare disease treatment portfolio
    • 15.3.10. Tourmaline Bio announces FDA clearance of Investigational New Drug application for TOUR006
  • 15.4. Strategy Analysis & Recommendation
    • 15.4.1. Sling Therapeutics, Inc.
    • 15.4.2. Amgen Inc.
    • 15.4.3. Viridian Therapeutics, Inc. by miRagen Therapeutics, Inc.
    • 15.4.4. ACELYRIN, INC.

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. ACELYRIN, INC.
  • 4. Amgen Inc.
  • 5. argenx SE
  • 6. Bausch & Lomb Incorporated
  • 7. Biocon Limited
  • 8. BioXpress Therapeutics SA
  • 9. Cipla Limited
  • 10. Dr. Reddy's Laboratories Ltd.
  • 11. Eli Lilly and Company
  • 12. F. Hoffmann-La Roche AG
  • 13. Genmab A/S
  • 14. GlaxoSmithKline PLC
  • 15. H. Lundbeck A/S
  • 16. Hetero Drugs Limited
  • 17. Immunovant, Inc.
  • 18. Intas Pharmaceuticals Ltd.
  • 19. Johnson & Johnson Services Inc.
  • 20. Lupin Limited
  • 21. Merck KGaA
  • 22. Novartis AG
  • 23. Pfizer, Inc.
  • 24. Regeneron Pharmaceuticals, Inc.
  • 25. Sling Therapeutics, Inc.
  • 26. Teva Pharmaceutical Industries Ltd.
  • 27. Viridian Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. THYROID EYE DISEASE TREATMENTS MARKET MULTI-CURRENCY
  • FIGURE 2. THYROID EYE DISEASE TREATMENTS MARKET MULTI-LANGUAGE
  • FIGURE 3. THYROID EYE DISEASE TREATMENTS MARKET RESEARCH PROCESS
  • FIGURE 4. THYROID EYE DISEASE TREATMENTS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2024 VS 2030 (%)
  • FIGURE 19. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 23. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. THYROID EYE DISEASE TREATMENTS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 29. THYROID EYE DISEASE TREATMENTS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. THYROID EYE DISEASE TREATMENTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. THYROID EYE DISEASE TREATMENTS MARKET DYNAMICS
  • TABLE 7. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY THYROID HORMONE CONTROL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY EYELID SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ORBITAL DECOMPRESSION SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY STRABISMUS SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE I TED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE II TED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY BLOOD TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY IMAGING TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ORBITAL ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY RADIOACTIVE IODINE UPTAKE TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY OUTPATIENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 107. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 113. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 115. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 121. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 123. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 126. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 129. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. INDONESIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 131. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 133. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 134. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 137. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. JAPAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 139. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 141. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 142. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 145. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. MALAYSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 150. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. PHILIPPINES THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 155. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 157. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 158. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 161. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. SINGAPORE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH KOREA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 171. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 173. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 174. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 177. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. TAIWAN THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 179. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 181. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 182. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 185. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. THAILAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 187. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 189. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 190. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 193. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. VIETNAM THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 204. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 206. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 207. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 210. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 211. DENMARK THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 212. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 214. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 215. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 216. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 218. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 219. EGYPT THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 220. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 222. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 223. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 224. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 226. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 227. FINLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 228. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 230. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 231. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 232. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 234. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 235. FRANCE THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 236. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 238. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 239. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 240. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 242. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 243. GERMANY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 244. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 246. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 247. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 248. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 250. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 251. ISRAEL THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 252. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 254. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 255. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 256. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 258. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 259. ITALY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 260. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 262. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 264. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 266. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 268. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 270. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 271. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 272. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 274. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 275. NIGERIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 276. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 278. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 279. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 280. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 282. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 283. NORWAY THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 284. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 285. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 286. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 287. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 288. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 289. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 290. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 291. POLAND THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 292. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 293. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 294. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 295. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 296. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 297. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 298. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 299. QATAR THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 300. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 301. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY MEDICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 302. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 303. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 304. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 306. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 307. RUSSIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 308. SAUDI ARABIA THYROID EYE DISEASE TREATMENTS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 309. SAUDI ARABIA THYROID EYE DISEASE TREATMENTS